Adrian Gottschalk - Jan 26, 2022 Form 4 Insider Report for Foghorn Therapeutics Inc. (FHTX)

Role
Chief Executive Officer, Director
Signature
/s /Allan Reine, M.D., Attorney-in-Fact for Adrian Gottschalk
Stock symbol
FHTX
Transactions as of
Jan 26, 2022
Transactions value $
$0
Form type
4
Date filed
1/28/2022, 03:26 PM
Previous filing
Aug 23, 2021
Next filing
Feb 22, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding FHTX Common Stock 146K Jan 26, 2022 Direct
holding FHTX Common Stock 325K Jan 26, 2022 See Footnote F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FHTX Stock Option (right to buy) Award $0 +440K $0.00 440K Jan 26, 2022 Common Stock 440K $14.87 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of 300,000 shares held by the Adrian H. Gottschalk 2021 Grantor Retained Annuity Trust dated November 29, 2021, of which the Reporting Person is the trustee and sole current beneficiary, and 25,225 shares held by the Adrian H. Gottschalk Living Trust dated September 8, 2009, of which the Reporting Person is the trustee.
F2 The option vested as to 25% of the underlying shares of common stock on January 26, 2023, the first anniversary of the of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter following such first anniversary until the option is fully vested.